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Familial juvenile hyperuricemic nephropathy: Detection of mu-
tations in the uromodulin gene in five Japanese families.
Background. Familial juvenile hyperuricemic nephropathy
(FJHN) is an autosomal-dominant disease characterized by hy-
peruricemia of underexcretion type, gout, and chronic renal fail-
ure. We previously reported linkage on chromosome 16p12 in
a large Japanese family designated as family 1 in the present
study. Recent reports on the discovery of mutations of the uro-
modulin (UMOD) gene in families with FJHN encouraged us
to screen UMOD mutations in Japanese families with FJHN,
including family 1.
Methods. Six unrelated Japanese families with FJHN were
examined for mutations of the UMOD gene by direct sequenc-
ing. To confirm the results of the mutation screening, parametric
linkage analyses were performed using markers in 16p12 region
and around other candidate genes of FJHN.
Results. Five separate heterozygous mutations (Cys52Trp,
Cys135Ser, Cys195Phe, Trp202Ser, and Pro236Leu) were found
in five families, including family 1. All mutations were co-
segregated with the disease phenotype in all families, except for
family 1, in which an individual in the youngest generation was
found as a phenocopy by the genetic testing. Revised multipoint
linkage analysis showed that the UMOD gene was located in
the interval showing logarithm of odds (LOD) score above 6.0.
One family carrying no mutation in the UMOD gene showed no
linkage to the medullary cystic kidney disease type 1 (MCKD1)
locus, the genes of hepatocyte nuclear factor-1b (HNF-1b), or
urate transporters URAT1 and hUAT.
Conclusion. Our results gave an evidence for the mutation
of the UMOD gene in the majority of Japanese families with
FJHN. Genetic heterogeneity of FJHN was also confirmed. Ge-
netic testing is necessary for definite diagnosis in some cases
especially in the young generation.
Key words: familial juvenile hyperuricemic nephropathy, FJHN, uro-
modulin, Tamm-Horsfall protein, glycoprotein-2, linkage analysis.
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Familial juvenile hyperuricemic nephropathy (FJHN)
(MIM 162000) is an autosomal-dominant disease charac-
terized by hyperuricemia of underexcretion type, gout,
and chronic renal failure. More than 50 families in vari-
ous ethnic groups have been described since Duncan and
Dixon first noted the disease in 1960 [1]. Affected family
members show the impairment of urate excretion before
puberty and usually develop hyperuricemia and gout af-
ter adolescence [2]. Renal function gradually deteriorates
and results in end-stage renal failure within 10 to 20 years.
Elucidation of the molecular defects accounting for this
disease should help understand the pathogenesis, early
diagnosis, and improvement of therapy. It may also help
identify the mechanisms underlying reduced urinary ex-
cretion of urate [3]. We have previously performed para-
metric linkage analysis on a large Japanese family with
FJHN and mapped the candidate gene locus on chromo-
some 16p12 [4, 5]. Several groups also reported linkage
to chromosome 16p11-p13 for European families with
FJHN [6–9].
Autosomal-dominant medullary cystic kidney disease
(MCKD) (MIM 174000) is a renal disorder character-
ized by the presence of small medullary cysts, a reduction
in urine concentrating ability, and a decrease in sodium
conservation. MCKD also progresses toward end-stage
renal failure during adulthood. Hyperuricemia and gout
have been reported in MCKD [10–12]. Several groups re-
ported linkage of MCKD on chromosome 1q21 [13–15].
Histopathologic findings at the late stage of both MCKD
and FJHN are common and characterized by chronic
tubulointerstitial nephropathy with focal areas of intersti-
tial fibrosis and inflammatory cell infiltration, thickening
of tubular basement membrane, and glomerulosclerosis.
These findings, however, are not specific and shared with
other familial renal diseases such as autosomal-recessive
juvenile-onset nephronophthisis (NPH) (MIM 256100)
[16, 17].
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Scolari et al [18] mapped a responsible gene locus on
chromosome 16p12 in an Italian family with MCKD,
which was designated later as MCKD2 (MIM 603860).
Hence, MCKD showing linkage to chromosome 1q21 was
designated as MCKD1. The same group screened muta-
tions in the uromodulin (UMOD) gene as a positional
candidate for MCKD2, but they reported failure in find-
ing consistent mutations [19]. Dahan et al [7] confirmed
the linkage between FJHN and markers within the 16p12
locus in a Belgian family and proposed that FJHN and
MCKD2 might be allelic disorders based on the similar
location of the gene loci as well as the clinical and patho-
logic resemblance between the diseases. Recently, Hart
et al [20] succeeded in positional cloning of a responsible
gene for FJHN in the locus on 16p11-p13. They found four
heterozygous mutations in the UMOD gene in three fam-
ilies with FJHN and in one family with MCKD2, proving
the theory of allelism of FJHN and MCKD2. Turner et al
[21] also reported five heterozygous missense mutations
in the UMOD gene in five unrelated families with FJHN.
In the present study, we describe a novel mutation in
the UMOD gene found in the large Japanese family in
which we have localized a responsible gene for FJHN to
16p12 [4, 5]. We found a phenocopy case in the family and
solved the inconsistency between the proposed disease
candidate intervals of us and those of other groups [6–9,
20]. We also report four different mutations in the UMOD
gene in another four Japanese families with FJHN. Be-
sides, we confirmed the genetic heterogeneity by finding
one FJHN family showing no mutation in the UMOD
gene and no linkage to other known candidate loci or
genes [6, 8, 9, 22]. We suppose that the remaining incon-
sistency in the proposed candidate intervals for FJHN
among the research groups is probably derived from phe-
nocopy and/or genotying errors. Genetic heterogeneity of
FJHN might also complicate the linkage analyses. Possi-
ble mechanisms for the mutations of the UMOD gene in
pathogenesis of FJHN are discussed.
METHODS
Pedigrees
Six unrelated Japanese pedigrees with FJHN were
studied (Fig. 1). Of the largest pedigree designated as
family 1 in the present study, the clinical and the bio-
chemical findings were reported previously by Yokota et
al [4] and a genome-wide linkage study by Kamatani et
al [5]. Informed consent was obtained from all subjects.
In family 1, DNA was extracted by the phenol extraction
method from the lymphoblastoid cell lines established
using Epstein-Barr virus. In families 2 to 6, DNA was
extracted from mononuclear cells separated from hep-
arinized peripheral blood. Criteria for diagnosis of affec-
tion with FJHN were described previously [4, 5]. Briefly,
an individual was considered to be affected if he or she
had either definitive severe renal failure or impaired urate
excretion as indicated by a fractional clearance of uric
acid (CUA/creatinine clearane) of less than 5.5% for men
or less than 7.8% for women.
Sequence analysis
For the sequence analysis of the UMOD gene, the
Genbank data NM 003361 for cDNA, NP 003352 for
protein, and AC106799 for genome were used. Intronic
primers for polymerase chain reaction (PCR) amplifica-
tion of all 12 exons of the UMOD gene were designed.
PCR was performed in a 50 lL reaction mixture con-
taining 20 ng template DNA, 1 unit KOD-plus DNA
polymerase (Toyobo, Osaka, Japan), 0.3 lmol/L each of
primers, 1 mmol/L MgSO4, and 0.2 mmol/L each of des-
oxynucleoside triphosphate (dNTP) in 1 × PCR buffer
(Toyobo). Amplified DNA was either treated with a
mixture of endonuclease I and shrimp alkaline phos-
phatase (ExoSAP-IT) (USB Corporation, Cleveland,
OH, USA) or purified with agarose gel electrophoresis
and was sequenced using the BigDye Terminator Cycle
Sequencing Kit, version 1, on an ABI 3700 DNA analyzer
(Applied Biosystems, Foster City, CA, USA).
Restriction endonuclease analysis in family 1
PCR amplification of exon 4 of the UMOD gene
was performed using genomic DNAs as templates and
the primers 5′-GGGGATGGATGGCACTGTGAGTG-
3′ and 5′-TTCCAGGCCTGGGATGAGGA-3′. The am-
plified DNAs were digested with Fok I (New England
Biolabs, Beverly, MA, USA) and electrophoresed on an
8% polyacrylamide gel. The gel was stained with ethid-
ium bromide and photographed under ultraviolet light.
Allele-specific (AS)-PCR assay
AS-PCR assays were performed using AS primers (de-
tails of primers are available on request). PCR ampli-
fications were performed using a SYBR Green I assay
mixture (SYBR Green PCR Master Mix) (Applied
Biosystems) with an ABI 7900HT system (Applied
Biosystems).
Parametric linkage analysis
Pairs of primers in the Linkage Mapping Set (Ap-
plied Biosystems) were used for known polymorphic mi-
crosatellite loci. For novel microsatellite markers, the
fluorescent dye primers were synthesized by Applied
Biosystems Japan (Tokyo, Japan). PCR and analyses of
data were performed as reported previously [5], except
for using an ABI 3700 DNA analyzer (Applied Biosys-
tems) for data collection and a Genotyper software, ver-
sion 3.5 (Applied Biosystems) for analyses. The MLINK
program, version 5.1, and the LINKMAP program,
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Fig. 1. Pedigrees of families with familial juvenile hyperuricemic nephropathy (FJHN). Hyperuricemia was defined as over 0.45 mmol/L
(=7.56 mg/dL) of serum uric acid; urate underexcretion, a fractional urate clearance of less than 5.5% for men or less than 7.8% for women.
The symbol of renal dysfunction indicates that an individual had undergone renal transplantation, was undergoing hemodialysis, or showed a serum
creatinine concentration of over 133 mmol/L (=1.5 mg/dL). Underlined numbers represent individuals who supplied DNA samples.
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Fig. 2. Restriction endonuclease analyses of exon 4 of the uromodulin (UMOD) gene. Individuals in each lane are indicated by the combination
of roman and arabic numerals. Roman numeral represents the number of the generation, and arabic numerals represent the number of individual
in each generation as presented in Figure 1. The upper bands indicated by m are derived from the polymerase chain reaction (PCR) products
containing the mutant allele, and the middle and lower bands indicated by WT are derived from the wild-type allele. Fourteen left-side lanes show
the digested PCR products from the individuals who had been considered as affected, while the remaining 19 lanes are those from the individuals
considered as unaffected. Note that the individual IV-21 carries only the wild-type allele of the UMOD gene.
version 5.1, supplied in the LINKAGE package [23] were
used for two-point and multipoint analyses, respectively.
Mapping information of known microsatellite markers
was based on the Marshfield genetic map. Parameters
were set as previously reported [5]. Briefly, the mode of
inheritance was set as autosomal-dominant. The pene-
trances for a homozygote without the disease allele, a
heterozygote, and a homozygote with the disease allele
were set at 0, 1, and 1, respectively. The frequencies of
marker alleles were set at even for every allele observed
for each marker. The frequency of the disease gene was
set at 0.001 in the general population.
RESULTS
Uromodulin sequence analysis
DNA sequence analysis of the 12 exons of the UMOD
gene was undertaken in 33 members in family 1, includ-
ing all 32 members who had previously been examined
in the linkage analysis [5]. A heterozygous missense mu-
tation of Pro236Leu was found in all affected individu-
als except VI-21 who belongs to the youngest generation
(Fig. 2). Subsequently, we examined other five families
with FJHN in the same way. In four of these five fam-
ilies, four different single nucleotide substitutions were
found to cause heterozygous missense mutations (i.e.,
Cys135Ser in family 2, Cys195Phe in family 3, Cys52Trp
in family 4, and Trp202Ser in family 5 (Table 1). No muta-
tion was found in family 6. All mutations in families 1 to 5
altered an evolutionary conserved residue in the UMOD
protein. In families 2 to 5, mutations were cosegregated
with the disease phenotype. None of the five mutations
was identified in any of 96 control genomic DNAs exam-
ined with sequencing and in other 180 control genomic
DNAs tested by AS-PCR.
Clinical findings of the individual VI-21 in family 1
To dissolve the inconsistency between genotype and
phenotype in VI-21 of family 1, we reexamined him clin-
Table 1. Summary of the mutations in the uromodulin (UMOD) gene
Amino
acid
Exona Mutationb positionb From To Phenotype Reference
4 c · 261T>G 52 Cys Trp FJHN Present study
(family 4)
4 c · 335G>A 77 Cys Tyr FJHN 21
4 c · 412G>T 103 Gly Cys MCKD 20
4 c · 481T>C 126 Cys Arg FJHN 21
4 c · 488A>G 128 Asn Ser FJHN 21
4 c · 508T>A 135 Cys Ser FJHN Present study
(family 2)
4 c · 548G>A 148 Cys Tyr FJHN 20
4 c · 634 660del 177–185 — — FJHN 20
4 c · 689G>T 195 Cys Phe FJHN Present study
(family 3)
4 c · 710G>C 202 Trp Ser FJHN Present study
(family 5)
4 c · 754T>C 217 Cys Arg FJHN 20
4 c · 812C>T 236 Pro Leu FJHN Present study
(family 1)
4 c · 869G>A 255 Cys Tyr FJHN 21
5 c · 1003T>G 300 Cys Gly FJHN 21
aAccording to the designation of the exons by Hart et al [20].
bAccording to the sequence of the mRNA (GenBank NM 003361) and the
amino acid (GenBank NP 003352) of human uromodulin.
ically. He was considered to be affected before the first
report of family 1 in 1991 [4] because of asymptomatic
hyperuricemia. Besides, multiple renal cysts have been
detected in the kidneys in repeated examinations with
ultrasonography. He has hypertension with no symptoms
of renal insufficiency at the age of 30 years. The hype-
ruricemia was at the level of 8.2 mg/dL. His fractional
clearance of uric acid was 5.23%, which was in the range
to be judged as affected in the criteria of the previous re-
ports [4, 5]. Judging from the present genetic data and the
recent reports [20, 21], the Pro236Leu mutation was the
causative mutation in family 1. Thus, VI-21 was indicated
to be a phenocopy case.
Linkage analysis of family 1
We reexamined the parametric linkage analysis in fam-
ily 1 under the setting that VI-21 was a phenocopy. A
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Fig. 3. Results of multipoint linkage analysis of the markers on chromosome 16p in family 1. The analysis was performed under the set-
ting that individual IV-21 was a phenocopy. Primer sequences of novel microsatellite markers are 5′-GGAGGTCGAGACTGCAGTG-3′ and
5′-ATTTCAAAGTCAGTTGCTGATGT-3′ for #118, 5′-GTATCAGTATGGACTCAGGAG-3′ and 5′-TGAAGAATCTTGTAGTGCCAGA-3′
for #238, 5′-CAGCTCAAACCCAGGTCAG-3′ and 5′-TTCCCAAACGATTCTATGGAG-3′ for #123, 5′-TTATCACAAACCCTTGTAGCA-
3′ and 5′-AAAAGTAAGAGAAGGAGCACG-3′ for ac002302a4, 5′-ACCTGCAGAGATTCTAATGGGA-3′ and 5′-GAGCTTGCAGT
GAGTAGACAGA-3′ for ac002299a3, and 5′-TCCAATTCAATTCATCCTAAAGCC-3′ and 5′-AGGACCAAGATACGCCAGTC-3′ for
ac002299a4.
two-point analysis by setting the penetrance at 1 showed
that the logarithm of odds (LOD) score was the highest
(5.76) for D16S772 at h = 0. Multipoint analysis yielded
the maximum LOD score of 6.35 at a novel marker of
#238 followed by 6.30 at D16S3046, 6.28 at D16S773,
6.25 at D16S772, 6.24 at #123, and 6.23 at ac002302a4
(Fig. 3). These results were compatible with that the dis-
ease in family 1 was caused by the missense mutation in
the UMOD gene locating between #123 and D16S773.
Linkage analysis in family 6
In family 6, we performed additional linkage analysis to
exclude the UMOD gene as the candidate gene and to ex-
amine other candidate loci and genes of FJHN reported
or speculated so far. We examined known and novel mi-
crosatellite markers in the MCKD1 locus (1q21) [13–15]
and those around the genes of UMOD, urate transporters
of URAT1 [24] and hUAT [25, 26], and hepatocyte nu-
clear factor (HNF)-1b [27] (Table 2). The UMOD gene
and the MCKD1 loci were clearly excluded for linkage.
Moreover, none of the loci of URAT1, hUAT, or HNF-1b
yielded the sufficient evidence for linkage.
DISCUSSION
We found five separate mutations in the UMOD gene in
five of six families with FJHN (83%), indicating that most
of Japanese families with FJHN are caused by mutations
of the UMOD gene. This rate (83%) is comparable to a
recent linkage study by Stacey et al [8] showing linkage to
16p11-p13 in five of seven European families with FJHN
(71%). Another recent linkage study by Stiburkova et al
[9] showing linkage to 16p11 in six of 15 European fam-
ilies with FJHN represented a much lower rate (40%).
Both the difficulty of accurate diagnosis in some cases
and the genetic heterogeneity of this disease probably
complicated the linkage analysis. Recently, Bleyer et al
[28] reported a clinical characterization of a family with
FJHN caused by a deletion of in-frame 9 amino acids
in the UMOD gene. They found in the members carry-
ing the mutation that renal insufficiency was the most
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Table 2. Two-point logarithm of odds (LOD) scores for family 6
Positiona
h
Genetic Physical
Locus (cM) (Kb) 0.0 0.1 0.2 0.3 0.4
MCKD1 (1q21)
D1S252 150.27 116705 −infinity −0.80 −0.33 −0.12 −0.03
D1S498 155.89 148077 −infinity −0.73 −0.35 −0.14 −0.03
D1S1153 161.05 152047 −infinity −0.65 −0.27 −0.10 −0.02
D1S1595 161.05 152466 −infinity −0.61 −0.28 −0.11 −0.03
D1S2635 165.62 155948 −infinity −1.12 −0.47 −0.18 −0.04
D1S484 169.68 157545 −infinity −1.13 −0.48 −0.18 −0.04
URAT1 (SLC22A12)
D11S4191 60.09 60251 −infinity −0.68 −0.32 −0.13 −0.03
URAT1 64620
ac044790a2b 64634 −0.35 −0.14 −0.06 −0.02 −0.00
ac044790a1c 64665 −0.01 −0.04 −0.05 −0.03 −0.01
D11S987 67.48 68143 −infinity −0.11 0.03 0.04 0.02
D11S4162 72.82 71198 0.29 0.24 0.18 0.10 0.03
UMOD
D16S3036 39.04 19452 −infinity −0.67 −0.32 −0.13 −0.03
#123 19631 −infinity −0.78 −0.34 −0.14 −0.03
UMOD 20272
D16S773 20608 −infinity −0.31 −0.12 −0.05 −0.01
D16S3046 40.65 20814 −infinity −0.30 −0.11 −0.04 −0.01
D16S772 20898 −0.10 −0.07 −0.04 −0.02 −0.00
hUAT (LGALS9)
D17S1857 43.01 16358 −0.05 −0.07 −0.06 −0.03 −0.01
hUAT 25810
D17S1824 49.67 26512 −infinity −0.84 −0.38 −0.16 −0.04
D17S1878 50.74 25963 −infinity −0.84 −0.38 −0.16 −0.04
D17S798 53.41 31139 −infinity −0.71 −0.32 −0.13 −0.03
HNF-1b
D17S927 58.25 34737 −infinity −0.49 −0.22 −0.09 −0.02
HNF-1b 35777
D17S1788 58.25 35817 0.51 0.37 0.23 0.11 0.03
Abbreviations are: MCKD1, medullary cystic kidney disease type 1; URAT1, urate transporter; UMOD, uromodulin; hUAT, human urate transporter; HNF-1b ,
hepatocyte nuclear factor-1b .
aAccording to the Marshfield genetic map and NCBI Map View build 33.
bPrimer sequences are 5′-CATGCATACTGGTTCACACTCAC-3′ and 5′-GGAGCACACAGGCATACAG-3′.
cPrimer sequences are 5′-TCCTCAGCATTGCTTGAATCA-3′ and 5′-CCTCCAGAAATCGACTGTCC-3′.
consistent finding after the age of 20 years and hyper-
uricemia was not universally present. Several unaffected
and control individuals were found to have fractional
clearance of uric acid of less than 5%. Our experience on
the individual IV-21 in family 1 also indicates the difficulty
in clinical diagnosis of FJHN, especially in the youngest
generation and the importance of a genetic test. Results of
the revised parametric linkage analyses of family 1 were
consistent with the discovery of mutation in the UMOD
gene and solved the inconsistency in the proposed dis-
ease candidate intervals between us and other groups
[6–9, 20].
The exclusion of the involvement of UMOD gene in
family 6 confirmed the genetic heterogeneity of FJHN
[6, 8, 9, 22]. Moreover, other possible candidates such as
MCKD1 locus [13–15], URAT1 gene [24], hUAT gene
[25, 26], and HNF-1b gene [27] gave no significant link-
age. Genome-wide linkage study of this family should
help finding another candidate locus responsible for
FJHN.
In spite of extensive studies on physicochemical and
biologic properties, in vivo functions of UMOD remain
obscure [29]. UMOD is an 85 kD glycoprotein initially
purified in 1985 from the urine of pregnant woman us-
ing lectin adherence columns as an in vitro immuno-
suppressive factor against T-cell and monocyte activity
[30]. In 1987, UMOD was revealed to be identical to
Tamm-Horsfall protein with the isolation of complemen-
tary DNA of human UMOD [31]. Tamm and Horsfall
[32] isolated the protein in 1950 from urine using the
salt precipitation method and characterized it as an in-
hibitor of viral hemagglutination. Tamm-Horsfall pro-
tein is the most abundant protein in normal urine and
a major component of urinary casts [29]. UMOD is syn-
thesized in kidney cells as a 640 amino acid precursor.
Upon translocation into the endoplasmic reticulum, the
24 amino acid signal peptide and the hydrophobic por-
tion of the C-terminus are removed, and then glycosyl-
phosphatidylinositol (GPI) anchor is attached to the
C-terminus. GPI-anchored UMOD is transported to
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the cell surface by exocytotic vesicles. At the cell sur-
face or in the endoplasmic reticulum lumen, UMOD is
cleaved again near the C-terminus, resulting in urinary
UMOD/Tamm-Horsfall protein [33–35]. UMOD con-
tains 48 cysteine residues which potentially form 24 in-
tramolecular disulfide bonds [31].
It is noteworthy that most of the mutations of the
UMOD gene are missense mutations located in the exon
4 [20, 21] (Table 1). There are only two exceptions; one is
an in-frame deletion of nine amino acids encoded in exon
4 [20], and the other is a missense mutation (Cys300Gly)
encoded in exon 5 [21]. Furthermore, the frequent mis-
sense mutations of cysteine residue (9/13) apparently rule
out the assumption that the mutations happened ran-
domly in any residue [(48/640)∧13]. These findings sug-
gest that the pathogenesis of FJHN associated with the
UMOD mutations is either the gain of function or the
dominant negative effect of the mutant UMOD rather
than the haplo insufficiency.
Aggregation of mutant proteins is one of the possibil-
ities for the gain of function mutation. The extratubular
UMOD/Tamm-Horsfall protein deposition as insolu-
ble aggregates has been documented in MCKD [36,
37]. A treatment of HeLa cells expressing recombinant
UMOD with an exogenous reducing agent such as 2-
mercaptoethanol results in drastic delay in the conversion
from a precursor to a mature UMOD [38]. The formation
of a correct set of interchain disulfide bonds is required
for UMOD to exit the endoplasmic reticulum [38, 39].
The UMOD molecules with aberrant folding due to the
missense mutations may aggregate for the problems in
posttranslational processing in the endoplasmic reticu-
lum [40, 41]. Several experimental and clinicopathologic
evidences demonstrated a proinflammatory potential of
aggregated UMOD/Tamm-Horsfall protein such as acti-
vation of neutrophils [42–44], stimulation of monocytes to
proliferate and release cytokines and gelatinases [45, 46],
and induction of humoral and cellular immune responses
[47]. Experimental inductions of autoimmune tubuloin-
terstitial nephritis by immunization with Tamm-Horsfall
protein were reported [48, 49]. These pro-inflammatory
potentials of UMOD/Tamm-Hosfall protein may relate
the tubulointerstitial nephritis in FJHN.
Studies of glycoprotein-2 (GP-2) suggest the dominant-
negative effect of the mutant UMOD. GP-2 is a 78 kD
membrane glycoprotein and the major component of
zymogen granule membranes of the exocrine pancreas.
GP-2 and UMOD define a new gene family based on the
structural similarity and other common characteristics,
including the GPI linkage, release from the apical mem-
brane of cells, and large aggregate formation in solution
after release from membrane [50–52]. The C-terminal
regions of GP-2 (Asp54-Phe530) and UMOD (Asp175-
His644) from rat show 53% identity, 86% similarity, and
26 conserved cysteine residues, including one epidermal
growth factor motif [50, 51]. All of the mutations of the
UMOD gene, which was located within the homologous
region to GP-2 occurred on conserved amino acid of both
proteins, namely, Cys195Phe, Trp202Ser, and Pro236Leu
in the present study as well as Cys217Arg [20], Cys255Tyr
[21], and Cys300Gly [21] in the previous reports. These
six residues are also conserved in GP-2 of human, dog,
mouse, and rat. As for the deletion mutation of nine
amino acids (HRTLDEYWR) [20], two residues (L and
R) are conserved in GP-2 of the four species. This evolu-
tional conservation of these residues suggests their impor-
tant roles for homologous functions of UMOD and GP-2.
Both UMOD/Tamm-Horsfall protein and GP-2 showed
pH- and ion-induced self-association mediated by hy-
drophobic interactions following pH-induced conforma-
tional changes [51, 53]. GPI anchors of both proteins may
facilitate the self-association, because diffusion coeffi-
cients for GPI-anchored membrane proteins were about
10-fold higher than values for peptide anchored mem-
brane proteins [51]. Based on these, Scheele, Fukuoka,
and Freedman [52] claimed that the self-association of
the GPI-linked forms of UMOD on the cisternal leaflet
of trans-Golgi membranes enable the sorting of Na-K-2
Cl cotransporter to the luminal surface. The polymeric
form of UMOD and GP-2 may function to maintain the
patency of tubular lumen, and prevent its collapse by
forming gel [54, 55]. The mutations of UMOD are likely
to change these conformational properties and interfere
self-association.
Renal urate transport is complex and not clearly under-
stood [56]. Urate is freely filtered at glomeruli, and then
nearly all urate is reabsorbed before the distal convo-
luted tubule, with the majority of urinary urate derived
from secretion. Both secretion and postsecretory reab-
sorption are supposed to occur in the proximal tubule.
Based on the parallel location of UMOD and Na-K-2 Cl
cotransport system in epithelial cells of thick ascending
loop of Henle (TALH) and the early distal convoluted
tubule, UMOD may be playing a role for the extremely
low water permeability that is necessary to maintain the
countercurrent multiplier system [57–61]. The UMOD
mutations may cause a defect in the impermeability of
TALH, which will result in influx of water from tubular
lumen to the medullary interstitium and lowering the uri-
nary concentrating ability by reducing medullary tonicity.
The mutations may diminish the number of Na-K-2 Cl co-
transporter on the luminal epithelial membrane of TALH
due to failure of the sorting mechanism. This condition
is similar to that seen following the chronic administra-
tion of loop diuretics or osmotic diuretics [62], associated
with hyperuricemia due to depletion of extracellular vol-
ume, a diminished glomerular filtration rate (GFR), and
increased reabsorption of urate in the proximal tubule
[62–64]. Similar mechanisms were supposed to be respon-
sible for hyperuricemia in patients with MCKD2 or FJHN
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[20]. The mutations of UMOD, however, may dimin-
ish GFR without depleting extracellular volume by acti-
vating tubuloglomerular feedback, because patients with
FJHN are usually normotensive to hypertensive even in
those without marked renal insufficiency [2, 4].
CONCLUSION
The present study confirmed the mutation of the
UMOD gene in the majority of the examined Japanese
families with FJHN. Genetic testing is necessary in some
members of the families for definite diagnosis of affec-
tion status especially in the young generation. Discov-
ery of the UMOD gene mutation as a cause of FJHN is
the first genetic abnormality found as a cause for hyper-
uricemia of an underexcretion type. Studies of pathogen-
esis of FJHN associated with mutations of the UMOD
gene should help understanding the mechanism of urate
transport in the kidney and finding therapy for chronic
progressive renal failure in FJHN.
ACKNOWLEDGMENT
This work was supported by a grant from the Japan Society for the
Promotion of Science (Grant for Genome Research of the Research
for the Future Program).
NOTE ADDED IN PROOF
During the proofreading process of this manuscript, Dahan et al [65]
and Rampoldi et al [66] reported the clustering of mutations in exon 4
of the UMOD gene and the intracellular accumulation of uromodulin
in tubular epithelia in patients with FJHN.
Reprint requests to Eiji Kudo, M.D., Ph.D., Division of Genetic Infor-
mation, Institute for Genome Research, The University of Tokushima,
3–18-15, Kuramoto-cho, Tokushima 770–8050, Japan.
E-mail: kudo@genome.tokushima-u.ac.jp
REFERENCES
1. DUNCAN H, DIXON ST J: Gout, familial hyperuricaemia and renal
disease. Q J Med 29:127–135, 1960
2. MCBRIDE MB, RIGDEN S, HAYCOCK GB, et al: Presymptomatic de-
tection of familial juvenile hyperuricaemic nephropathy in children.
Pediatr Nephrol 12:357–364, 1998
3. BECKER MA, ROESSLER BJ: Hyperuricemia and gout, in Metabolic
and Molecular Basis of Inherited Disease (7th ed), edited by Scriver
CR, Beaudet AL, Sly WS, Valle D, New York, McGraw-Hill Com-
pany, 1995, pp 1655–1678
4. YOKOTA N, YAMANAKA H, YAMAMOTO Y, et al: Autosomal dominant
transmission of gouty arthritis with renal disease in a large Japanese
family. Ann Rheum Dis 50:108–111, 1991
5. KAMATANI N, MORITANI M, YAMANAKA H, et al: Localization of
a gene for familial juvenile hyperuricemic nephropathy causing
underexcretion-type gout to 16p12 by genome-wide linkage analy-
sis of a large family. Arthritis Rheum 43:925–929, 2000
6. STIBURKOVA B, MAJEWSKI J, SEBESTA I, et al: Familial juvenile hype-
ruricemic nephropathy: Localization of the gene on chromosome
16p11.2 and evidence for genetic heterogeneity. Am J Hum Genet
66:1989–1994, 2000
7. DAHAN K, FUCHSHUBER A, ADAMIS S, et al: Familial juvenile hype-
ruricemic nephropathy and autosomal dominant medullary cystic
kidney disease type 2: Two facets of the same disease? J Am Soc
Nephrol 12:2348–2357, 2001
8. STACEY JM, TURNER JJO, HARDING B, et al: Genetic mapping stud-
ies of familial juvenile hyperuricemic nephropathy on chromosome
16p11-p13. J Clin Endocrinol Metabol 88:464–470, 2003
9. STIBURKOVA B, MAJEWSKI J, HODANOVA K, et al: Familial juvenile hy-
peruricaemic nephropathy (FJHN): Linkage analysis in 15 families,
physical and transcriptional characterization of the FJHN critical
region on chromosome 16p11.2 and the analysis of seven candidate
genes. Eur J Hum Genet 11:145–154, 2002
10. NEWCOMBE DS: Gouty arthritis and polycystic kidney disease. Ann
Intern Med 79:605, 1973
11. THOMPSON GR, WEISS JJ, GOLDMAN RT, RIGG GA: Familial occur-
rence of hyperuricemia, gout, and medullary cystic disease. Arch
Intern Med 138:1614–1617, 1978
12. MEJIAS E, NAVAS J, LLUBERES R, MARTINEZ-MALDONADO M: Hyper-
uricemia, gout, and autosomal dominant polycystic kidney disease.
Am J Med Sci 297:145–148, 1989
13. CHRISTODOULOU K, TSINGIS M, STAVROU C, et al: Chromosome 1 lo-
calization of a gene for autosomal dominant medullary cystic kidney
disease (ADMCKD). Hum Mol Genet 7:905–911, 1998
14. AURANEN M, ALA-MELLO S, TURUNEN JA, JARVELA I: Further
evidence for linkage of autosomal-dominant medullary cystic
kidney disease on chromosome 1q21. Kidney Int 60:1225–1232,
2001
15. PARVARI R, SHNAIDER A, BASOK A, et al: Clinical and genetic charac-
terization of an autosomal dominant nephropathy. Am J Med Genet
99:204–209, 2001
16. HILDEBRANDT F, OTTO E: Molecular genetics of nephronophthisis
and medullary cystic kidney disease. J Am Soc Nephrol 11:1753–
1761, 2000
17. SCOLARI F, VIOLA BF, GHIGGERI GM, et al: Towards the identifica-
tion of (a) gene(s) for autosomal dominant medullary cystic kidney
disease. J Nephrol 16:321–328, 2003
18. SCOLARI F, PUZZER D, AMOROSO A, et al: Identification of a new
locus for medullary cystic disease, on chromosome 16p12. Am J
Hum Genet 64:1655–1660, 1999
19. PIRULLI D, PUZZER D, DE FUSCO M, et al: Molecular analysis of
uromodulin and SAH genes, positional candidates for autosomal
dominant medullary cystic kidney disease linked to 16p12. J Nephrol
14:392–396, 2001
20. HART TC, GORRY MC, HART PS, et al: Mutations of the UMOD gene
are responsible for medullary cyctic kidney disease 2 and familial ju-
venile hyperuricaemic nephropathy. J Med Genet 39:882–892, 2002
21. TURNER JJO, STACEY JM, HARDING B, et al: Uromodulin mutations
cause familial juvenile hyperuricemic nephropathy. J Clin Endi-
crinol Metab 88:1398–1401, 2003
22. OHNO I, ICHIDA K, OKABE H, et al: Familial juvenile gouty nephropa-
thy: Exclusion of 16p12 from the candidate locus. Nephron 92:573–
575, 2002
23. TERWILLIGER JD, OTT J: Handbook of Human Genetic Linkage, Bal-
timore, Johns Hopkins University Press, 1994
24. ENOMOTO A, KIMURA H, CHAIROUNGDUA A, et al: Molecular identi-
fication of a renal urate-anion exchanger that regulates blood urate
levels. Nature 417:447–451, 2002
25. LIPKOWITZ MS, LEAL-PINTO E, RAPPOPORT JZ, et al: Functional re-
constitution, membrane targeting, genomic structure, and chro-
mosomal localization of a human urate transporter. J Clin Invest
107:1103–1115, 2001
26. HYINK DP, RAPPOPORT JZ, WILSON PD, ABRAMSON RG: Expression
of the urate transporter/channel is developmentally regulated in
human kidneys. Am J Physiol 281:F875–F886, 2001
27. BINGHAM C, ELLARD S, VAN’T HOFF WG, et al: Atypical familial
juvenile hyperuricemic nephropathy associated with a hepatocyte
nuclear factor-1bmutation. Kidney Int 63:1645–1651, 2003
28. BLEYER AJ, WOODARD AS, SHIHABI Z, et al: Clinical characteriza-
tion of a family with a mutation in the uromodulin (Tamm-Horsfall
glycoprotein) gene. Kidney Int 64:36–42, 2003
29. KUMAR S, MUCHMORE A: Tamm-Horsfall protein—Uromodulin
(1950–1990). Kidney Int 37:1395–1401, 1990
30. MUCHMORE AV, DECKER JM: Uromodulin: A unique 85-kilodalton
immunosuppressive glycoprotein isolated from urine of pregnant
women. Science 229:479–481, 1985
Kudo et al: Uromodulin mutations in FJHN 1597
31. PENNICA D, KOHR WJ, KUANG W-J, et al: Identification of human
uromodulin as the Tamm-Horsfall urinary glycoprotein. Science
236:83–88, 1987
32. TAMM I, HORSFALL FL: Characterization and separation of an in-
hibitor of viral hemaggultination present in urine. Proc Soc Exp
Biol Med 74:108–114, 1950
33. RINDLER MJ, NAIK SS, LI N, et al: Uromodulin (Tamm-Horsfall
glycoprotein/uromucoid) is a phoshatidylinositol-linked membrane
protein. J Biol Chem 265:20784–20789, 1990
34. CAVALLONE D, MALAGOLINI N, SERAFINI-CESSI F: Mechanism of
release of urinary Tamm-Horsfall glycoprotein from the kidney
GPI-anchored counterpart. Biochem Biophys Res Commun 280:
110–114, 2001
35. FUKUOKA S, KOBAYASHI K: Analysis of the C-terminal structure of
urinary Tamm-Horsfall protein reveals that the release of the gly-
cosyl phosphatidylinositol-anchored counterpart from the kidney
occurs by phenylalanine-specific proteolysis. Biochem Biophys Res
Commun 289:1044–1048, 2001
36. ZAGER RA, COTRAN RS, HOYER JR: Pathologic localization of
Tamm-Horsfall protein in interstitial deposits in renal disease. Lab
Invest 38:52–57, 1978
37. RESNICK JS, SISSON S, VERNIER RL: Tamm-Horsfall protein: Abnor-
mal localization in renal disease. Lab Invest 38:550–555, 1978
38. MALAGOLINI N, CAVALLONE D, SERAFINI-CESSI F: Intracellular trans-
port, cell-surface exposure and release of recombinant Tamm-
Horsfall glycoprotein. Kidney Int 52:1340–1350, 1997
39. SERAFINI-CESSI F, MALAGOLINI N, HOOPS TC, RINDLER MJ: Biosyn-
thesis and oligosaccharide processing of human Tamm-Horsfall gly-
coprotein permanently expressed in HeLa cells. Biochem Biophys
Res Commun 194:784–790, 1993
40. GETHING M-J, SAMBROOK J: Protein folding in the cell. Nature
355:33–45, 1992
41. BROSS P, CORYDON TJ, ANDERSEN BS, et al: Protein misfolding and
degradation in genetic diseases. Hum Mutat 14:186–198, 1999
42. HORTON JK, DAVIS M, TOPLEY N, et al: Activation of the inflamma-
tory response of neutrophils by Tamm-Horsfall glycoprotein. Kid-
ney Int 37:717–726, 1990
43. THOMAS DB, DAVIES M, PETERS JR, WILLIAMS JD: Tamm Horsfall
protein binds to a single class of carbohydrate specific receptors on
human neutrophils. Kidney Int 44:423–429, 1993
44. CAVALLONE D, MALAGOLINI N, SERAFINI-CESSI F: Binding of human
neutrophils to cell-surface anchored Tamm-Horsfall glycoprotein
in tubulointerstitial nephritis. Kidney Int 55:1787–1799, 1999
45. THOMAS DB, DAVIES M, WILLIAMS JD: Release of gelatinase and
superoxide from human mononuclear phagocytes in response to
particulate Tamm Horsfall protein. Am J Pathol 142:249–260, 1993
46. SU S-J, CHANG K-L, LIN T-M, et al: Uromodulin and Tamm-Horsfall
protein induce human monocytes to secrete TNF and express tissue
factor. J Immunol 158:3449–3456, 1997
47. THOMAS DBL, DAVIES M, WILLIAMS JD: Tamm-Horsfall protein: an
aetiological agent in tubulointerstitial disease? Exp Nephrol 1:281–
284, 1993
48. HOYER JR: Tubulointerstitial immune complex nephritis in rats im-
munized with Tamm-Horsfall protein. Kidney Int 17:284–292, 1980
49. MAYRER AR, KASHGARIAN M, RUDDLE NH, et al: Tubulointerstitial
nephritis and immunologic responses to Tamm-Horsfall protein in
rabbits challenged with homologous urine or Tamm-Horsfall pro-
tein. J Immunol 128:2634–2642, 1982
50. HOOPS TC, RINDLER MJ: Isolation of the cDNA encoding
glycoprotein-2 (GP-2), the major zymogen granule membrane pro-
tein. J Biol Chem 266:4257–4263, 1991
51. FUKUOKA S, FREEDMAN SD, YU H, et al: GP-2/THP gene family en-
codes self-binding glycosylphosphatidylinositol-anchored proteins
in apical secretory compartments of pancreas and kidney. Proc Natl
Acad Sci USA 89:1189–1193, 1992
52. SCHEELE GA, FUKUOKA S, FREEDMAN SD: Role of the GP2/THP
family of GPI-anchored proteins in membrane trafficking during
regulated exocrine secretion. Pancreas 9:139–149, 1994
53. FREEDMAN SD, SCHEELE GA: Reversible pH-induced homophilic
binding of GP2, a glycosyl phosphatidylinositol-anchored protein
in pancreatic zymogen granule membranes. Eur J Cell Biol 61:229–
238, 1993
54. WIGGINS RC: Uromucoid (Tamm-Horsfall glycoprotein) forms
different polymeric arrangements on a filter surface under dif-
ferent physicochemical conditions. Clin Chim Acta 162:329–340,
1987
55. GRONDIN G, ST-JEAN P, BEAUDOIN AR: Cytochemical and immuno-
cytochemical characterization of a fibrillar network (GP2) in pan-
creatic juice: Possible role as a sieve in the pancreatic ductal system.
Eur J Cell Biol 57:155–164, 1992
56. SICA DA, SCHOOLWERTH AC: Renal handling of organic anions and
cations: Excretion of uric acid, in The Kidney (6th ed) (vol 1), edited
by Brenner BM, Philadelphia, WB Saunders Company, 2000, pp
680–700
57. SIKRI KL, FOSTER CL, BLOOMFIELD FJ, MARSHALL RD: Localiza-
tion by immunofluorescence and by light- and electron-microscopic
immunoperoxidase techniques of Tamm-Horsfall glycoprotein in
adult hamster kidney. Biochem J 181:525–532, 1979
58. HOYER JR, SISSON SP, VERNIER RL: Tamm-Horsfall glycoprotein:
Ultrastructural immunoperoxidase localization in rat kidney. Lab
Invest 41:168–173, 1979
59. BACHMANN S, KOEPPEN-HAGEMANN I, KRIZ W: Ultrastructural lo-
calization of Tamm-Horsfall glycoprotein (THP) in rat kidney as
revealed by protein A-gold immunocytochemistry. Histochemistry
83:531–538, 1985
60. MATTEY M, NAFTALIN L: Mechanoelectrical transduction, ion move-
ment and water stasis in uromodulin. Experientia 48:975–980,
1992
61. HOYER JR, SEILER MW: Pathophysiology of Tamm-Horsfall protein.
Kidney Int 16:279–289, 1979
62. JACKSON EK: Diuretics, in Goodman and Gilman’s The Pharma-
cological Basis of Therapeutics (10th ed), edited by Hardman JG,
Limbird LE, Gilman AG, New York, McGraw-Hill Company, 2001,
pp 757–787
63. STEELE TH, OPPENHEIMER S: Factors affecting urate excretion fol-
lowing diuretic administration in man. Am J Med 47:564–574,
1969
64. KAHN AM: Effect of diuretics on the renal handling of urate. Semin
Nephrol 8:305–314, 1988
65. DAHAN K, DEVUYST O, SMAERS M, et al: A cluster of mutations in
the UMOD gene causes familial juvenile hyperuricemic nephropa-
thy with abnormal expression of uromodulin. J Am Soc Nephrol
14:2883–2893, 2003
66. RAMPOLDI L, CARIDI G, SANTON D, et al: Allelism of MCKD, FJHN
and GCKD caused by impairment of uromodulin export dynamics.
Hum Mol Genet 12:3369–3384, 2003
